220 related articles for article (PubMed ID: 37730533)
21. Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.
Lee JM; Jang BK; Lee YJ; Choi WY; Choi SM; Chung WJ; Hwang JS; Kang KJ; Kim YH; Chauhan AK; Park SY; Tak WY; Kweon YO; Kim BS; Lee CH
Clin Mol Hepatol; 2016 Mar; 22(1):160-7. PubMed ID: 27044767
[TBL] [Abstract][Full Text] [Related]
22. Hepatocellular carcinoma in the elderly: Meta-analysis and systematic literature review.
Hung AK; Guy J
World J Gastroenterol; 2015 Nov; 21(42):12197-210. PubMed ID: 26576104
[TBL] [Abstract][Full Text] [Related]
23. Meta-analysis on radiofrequency ablation in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Cao JH; Zhou J; Zhang XL; Ding X; Long QY
J Huazhong Univ Sci Technolog Med Sci; 2014 Oct; 34(5):692-700. PubMed ID: 25318879
[TBL] [Abstract][Full Text] [Related]
24. TACE combined with dendritic cells and cytokine-induced killer cells in the treatment of hepatocellular carcinoma: A meta-analysis.
He G; Zheng C; Huo H; Zhang H; Zhu Z; Li J; Zhang H
Int Immunopharmacol; 2016 Nov; 40():436-442. PubMed ID: 27716591
[TBL] [Abstract][Full Text] [Related]
25. Novel biomarkers GEP/ABCB5 regulate response to adjuvant transarterial chemoembolization after curative hepatectomy for hepatocellular carcinoma.
Chong CC; Cheung ST; Cheung YS; Chan AW; Chan SL; Yu SC; Lai PB
Hepatobiliary Pancreat Dis Int; 2018 Dec; 17(6):524-530. PubMed ID: 30413348
[TBL] [Abstract][Full Text] [Related]
26. Hepatic Re-resection Versus Transarterial Chemoembolization for the Treatment of Recurrent Hepatocellular Carcinoma after Initial Resection: a Systematic Review and Meta-analysis.
Wang DY; Liu L; Qi XS; Su CP; Chen X; Liu X; Chen J; Li HY; Guo XZ
Asian Pac J Cancer Prev; 2015; 16(13):5573-8. PubMed ID: 26225712
[TBL] [Abstract][Full Text] [Related]
27. Survival benefit of hepatic resection versus transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis.
Zhang XP; Wang K; Li N; Zhong CQ; Wei XB; Cheng YQ; Gao YZ; Wang H; Cheng SQ
BMC Cancer; 2017 Dec; 17(1):902. PubMed ID: 29282010
[TBL] [Abstract][Full Text] [Related]
28. Comparing the efficacy and safety of local-regional treatments for hepatocellular carcinoma with portal/hepatic vein tumor thrombosis in China: a network meta-analysis of randomized controlled trials.
Wu QQ; Gao H; Du SS; Chen YX; Hu Y; Yang P; Hou JZ; Zeng ZC
J BUON; 2021; 26(5):1950-1957. PubMed ID: 34761604
[TBL] [Abstract][Full Text] [Related]
29. An overview of evidence-based management of hepatocellular carcinoma: a meta-analysis.
Salhab M; Canelo R
J Cancer Res Ther; 2011; 7(4):463-75. PubMed ID: 22269411
[TBL] [Abstract][Full Text] [Related]
30. Does postoperative adjuvant transarterial chemoembolization benefit for all patients with hepatocellular carcinoma combined with microvascular invasion: a meta-analysis.
Wang L; Ke Q; Lin N; Zeng Y; Liu J
Scand J Gastroenterol; 2019 May; 54(5):528-537. PubMed ID: 31081401
[No Abstract] [Full Text] [Related]
31. The combination of transcatheter arterial chemoembolisation (TACE) and thermal ablation versus TACE alone for hepatocellular carcinoma.
Liu B; Zhang Y; Chen H; Li W; Tsochatzis E
Cochrane Database Syst Rev; 2022 Jan; 1(1):CD013345. PubMed ID: 34981511
[TBL] [Abstract][Full Text] [Related]
32. Transcatheter arterial chemoembolization combined with interferon-α is safe and effective for patients with hepatocellular carcinoma after curative resection.
Zuo CH; Xia M; Liu JS; Qiu XX; Lei X; Xu RC; Liu HC; Li JL; Li YG; Li QL; Xiao H; Hong Y; Wang XH; Zhu HZ; Wu QF; Burns M; Liu C
Asian Pac J Cancer Prev; 2015; 16(1):245-51. PubMed ID: 25640360
[TBL] [Abstract][Full Text] [Related]
33. Meta-analysis of radiofrequency ablation in combination with transarterial chemoembolization for hepatocellular carcinoma.
Ni JY; Liu SS; Xu LF; Sun HL; Chen YT
World J Gastroenterol; 2013 Jun; 19(24):3872-82. PubMed ID: 23840128
[TBL] [Abstract][Full Text] [Related]
34. Transcatheter Arterial Chemoembolization Plus Radiotherapy Compared With Chemoembolization Alone for Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.
Huo YR; Eslick GD
JAMA Oncol; 2015 Sep; 1(6):756-65. PubMed ID: 26182200
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant Transarterial chemoembolization does not influence recurrence-free or overall survival in patients with combined hepatocellular carcinoma and Cholangiocarcinoma after curative resection: a propensity score matching analysis.
Liu WR; Tian MX; Tao CY; Tang Z; Zhou YF; Song SS; Jiang XF; Wang H; Zhou PY; Qu WF; Fang Y; Ding ZB; Zhou J; Fan J; Shi YH
BMC Cancer; 2020 Jul; 20(1):642. PubMed ID: 32650743
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant transarterial chemoembolization after curative resection of hepatocellular carcinoma: propensity score analysis.
Jiang JH; Guo Z; Lu HF; Wang XB; Yang HJ; Yang FQ; Bao SY; Zhong JH; Li LQ; Yang RR; Xiang BD
World J Gastroenterol; 2015 Apr; 21(15):4627-34. PubMed ID: 25914472
[TBL] [Abstract][Full Text] [Related]
37. Cidan Capsule in Combination with Adjuvant Transarterial Chemoembolization Reduces Recurrence Rate after Curative Resection of Hepatocellular Carcinoma: A Multicenter, Randomized Controlled Trial.
Zheng DH; Yang JM; Wu JX; Cheng SQ; Zhang SG; Wu D; Li AJ; Fu XH; Li X; Qi FC; Duan WH; Chen JH; Yang ZY; Liang L; Zeng JX; Zheng WD; Wu MC
Chin J Integr Med; 2023 Jan; 29(1):3-9. PubMed ID: 35915317
[TBL] [Abstract][Full Text] [Related]
38. Adjuvant transarterial chemoembolization after curative resection of hepatocellular carcinoma: a non-randomized comparative study.
Xi T; Lai EC; Min AR; Shi LH; Wu D; Xue F; Wang K; Yan Z; Xia Y; Shen F; Lau WY; Wu MC
Hepatogastroenterology; 2012 Jun; 59(116):1198-203. PubMed ID: 22580673
[TBL] [Abstract][Full Text] [Related]
39. Optimal adjuvant therapy for resected hepatocellular carcinoma: a systematic review with network meta-analysis.
Zhu GQ; Shi KQ; Yu HJ; He SY; Braddock M; Zhou MT; Chen YP; Zheng MH
Oncotarget; 2015 Jul; 6(20):18151-61. PubMed ID: 26061709
[TBL] [Abstract][Full Text] [Related]
40. [Network Meta-analysis of oral Chinese patent medicine for adjuvant treatment of primary liver cancer].
Zhang RR; Shao MY; Fu Y; Zhao RX; Wang JW; Li M; Zhao YX; Shao FL
Zhongguo Zhong Yao Za Zhi; 2021 May; 46(9):2333-2343. PubMed ID: 34047138
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
